News
STORM Therapeutics is looking to harness the power of RNA epigenetics by honing in on the modulation of RNA-modifying enzymes.
Read more
STORM Therapeutics and Evotec to exploit RNA modulating enzymes for novel epigenetic drug discovery
Read more
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as...
Read more
Two recent features in the 23 February 2017 edition of Nature discuss how newly discovered RNA modifications revolutionise our understanding of the regulation of gene expression...
Read more
STORM Therapeutics, a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, has received...
Read more